Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Agreement with University of Michigan for Testing of Latest Psychedelic Drug Candidate
San Diego-based Tryp Therapeutics is developing new drug candidates with the aim of treating medical conditions that currently have limited effective therapy Tryp has solidified an agreement with the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science to test synthetic psychedelic drug candidate TRP-8803 to advance its use in upcoming clinical trials The Company has also established an agreement with the University of Florida to test its lead drug candidate — TRP-8802 — for certain eating disorders Psychedelics are beginning to gain new respect and attention for addressing select neurological conditions as scientists,…